Anzeige
Mehr »
Login
Mittwoch, 17.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Ausbruch – startet jetzt die massive FDA-Rallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QB4E | ISIN: IL0011651580 | Ticker-Symbol:
NASDAQ
17.04.24
19:25 Uhr
0,891 US-Dollar
+0,080
+9,80 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
PAINREFORM LTD Chart 1 Jahr
5-Tage-Chart
PAINREFORM LTD 5-Tage-Chart

Aktuelle News zur PAINREFORM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiPainReform prices its $4M offering at $0.80 apiece; shares fall1
DiPAINREFORM LTD. - 6-K, Report of foreign issuer-
MoPAINREFORM LTD. - F-1/A, Registration statement for certain foreign private issuers1
09.04.PAINREFORM LTD. - 6-K, Report of foreign issuer1
09.04.PainReform Ltd: PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions47TEL AVIV, Israel, April 09, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation...
► Artikel lesen
09.04.EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions1
02.04.PAINREFORM LTD. - 6-K, Report of foreign issuer1
02.04.PainReform Ltd: PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy63TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation...
► Artikel lesen
02.04.EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug1
01.03.PainReform files to sell shares1
01.03.PAINREFORM LTD. - F-1, Registration statement for certain foreign private issuers2
01.03.PainReform advances in phase 3 bunionectomy trial1
01.03.PAINREFORM LTD. - 6-K, Report of foreign issuer2
01.03.PainReform Ltd: PainReform Provides Year-End Business Update259Reports continued enrollment in the second part of the Phase 3 clinical trial in bunionectomy Remains on track to announce top-line data by mid-2024 TEL AVIV, Israel, March 01, 2024 (GLOBE NEWSWIRE)...
► Artikel lesen
29.02.PAINREFORM LTD. - 20-F, Annual and transition report of foreign private issuers2
22.01.DealFlow Events: PainReform to Present at the Microcap Conference in Atlantic City336Tel Aviv, Israel--(Newsfile Corp. - January 22, 2024) - PainReform Ltd. (NASDAQ: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation...
► Artikel lesen
22.01.PainReform Ltd: PainReform to Present at the Microcap Conference in Atlantic City1
12.01.PainReform files to sell 968,545 ordinary shares for holders1
03.01.PAINREFORM LTD. - 6-K, Report of foreign issuer1
03.01.PainReform Ltd: PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief279TEL AVIV, Israel, Jan. 03, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation...
► Artikel lesen
Seite:  Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1